We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
Highlights Enhanced understanding of SCLC subtypes drives tailored treatment approaches. I...
Read ArticleASX starts week lower with mining stocks under pressure Resolute mining plunges after CEO detained...
Read ArticleASX rallies broadly as tech stocks lead Commonwealth Bank hits record, Neuren jumps Asian markets r...
Read ArticleASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results...
Read ArticleThe S&P/ASX 200 fell 1.3% in October with small cap companies outperforming S&P Dow Jones I...
Read ArticleASX opens November lower, led by financial sector sell-off Macquarie Group fell after profit decli...
Read ArticleASX slips amid earnings updates and company meetings AGL drops over 6pc after downgrade, while...
Read ArticleASX rises following Wall Street’s lead Cettire drops 12pc after disappointing earnings update Ret...
Read ArticleASX gains as energy and mining stocks rally Arcadium Lithium surges after Rio acquisition, while...
Read ArticleASX fell as mining stocks dropped on China’s lack of stimulus Brent oil dipped below US$80 Big lit...
Read ArticleASX 200 index falls despite gains in energy stocks Smaller oil and gas firms benefit from rising...
Read ArticleASX edges down in a quiet market Pilbara Minerals falls 5pc as share block sale is reported We...
Read ArticleGood morning, and welcome to Stockhead’s Top 10 at somewhere near 11-ish, which is meant to highligh...
Read ArticleASX flattish amid rising Middle East tensions Crude oil prices surge 5pc, pushing oil stocks hig...
Read ArticleArgent Biopharma packs its bags for London on a one-way ticket Patrys shares slump 50% on cancellat...
Read ArticleGood morning, and welcome to Stockhead’s Top 10 at somewhere near 11-ish, which is meant to highligh...
Read ArticleHealthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as...
Read ArticleASX200 hits record high driven by US Fed interest rate cut Mining stocks surge as iron ore prices...
Read ArticleASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing;...
Read ArticleASX up as earnings season rolls on; Origin down 10pc, Telstra up 3pc Australia’s unemployment rate...
Read ArticleASX rises circa 0.5pc Consumer stocks in focus this week SGQ and PHX lead small caps Aussie stoc...
Read ArticleGood morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highligh...
Read ArticleS&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expec...
Read ArticleThe EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-l...
Read ArticleGood morning, and welcome to Stockhead’s Top 10 at shortly-after-11-ish, which is meant to highlight...
Read ArticleThe ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biot...
Read ArticleS&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biot...
Read ArticleResearch shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase th...
Read ArticleStockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) pe...
Read ArticleASX Health sector was in correction territory in April Why is the health sector different from othe...
Read ArticleThere’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to c...
Read ArticleThe ASX200 closed +0.5% higher on Tuesday on the back of a big lift in the Mining sector. Lithium s...
Read ArticlePatrys (ASX: PAB) has released positive data from pre-clinical studies using deoxymabs PAT-DX1 and P...
Read ArticlePatrys’ deoxymabs data on vasculitis disease presented Next Science’s BLASTX data published Patr...
Read ArticleASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essenti...
Read ArticleLocal markets started slow before ripping into an all-time intraday high 10 of 11 sectors high...
Read ArticleViking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
Read ArticleGood morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticleBenchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Di...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleAccording to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleBrisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “gam...
Read ArticleSmall cap health stocks are not known to pay dividends But there’s a handful of such stocks on the...
Read ArticleThe ASX fell this morning and – sadly – just never recovered. It’s down 0.64%. Aside from Happy Tim...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some of the strongest-performing ASX stocks that might...
Read ArticlePatry receives positive toxicology reports on PAT-DX1 Immutep says triple combination trial of Efti...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleASX sinks to -0.4% before slogging its way back to -0.22% for the day. Tech stocks were all over th...
Read ArticleASX falls 0.17% ahead of Chalmers dropping The Budget on the nation Financials led the pack today,...
Read ArticleThe S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chi...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleStable commodity prices and mining stocks saw the ASX break its seven-week losing streak. The ASX...
Read ArticleASX closes up 0.78%, while XEC rises 1.91% following global markets higher Morningstar warns of pos...
Read ArticleAs the first quarter of this calendar year wraps up, Sayona Mining (SYA) and Piedmont Lithium (PLL)...
Read ArticlePatrys (PAB) shares are slumping on Friday after the company flagged delays over the phase one clini...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleAustralian therapeutic antibody development company Patrys (ASX:PAB) has announced results f...
Read ArticleShareCafeASX falls 1.4% to three-month low by Peter Milios At the closing bell, the S&P/ASX 20...
Read ArticlePatrys (PAB) claims a recent pre-clinical study of its PAT-DX3 drug shows the product could treat ca...
Read ArticleShareCafeASX down 1.91% at noon to lowest point since Jan by Peter Milios Earlier today, the S&...
Read Article14 Mar 2023 - A snapshot of the stocks on the move featuring Patrys (ASX:PAB), Mt Monger Resources (...
Read ArticleShareCafeStocks of the Hour: PAB, MTM, IMM Patrys (ASX:PAB) has announced t...
Read ArticlePatrys says pre-clinical data supports its drug’s synthetic lethality mechanism Alterity granted pa...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticlePatrys (PAB) subsidiary Nucleus Therapeutics receives a $3.35 million research and development tax i...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticleBoth the ASX 200 and small cap index were in the green today A massive 11 out 11 sectors finished h...
Read ArticleShareCafeWebinar Recap – HPC, PAB, MKR & SRR Catch up on the full presentations form the Hydrat...
Read ArticleShareCafePatrys (ASX: PAB) – Webinar presentation James Campbell – Managing Director & CEO Patr...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleNov 16 (Reuters) - Patrys Ltd: * PATRYS APPOINTS DR CHARMAINE GITTLESON AS CHAIRMAN Source text for...
Read ArticleWe take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks fr...
Read ArticlePatrys (PAB) confirms its PAT-DX3 antibody can cross the blood-brain barrier in healthy animals afte...
Read Article17 Oct 2022 - A snapshot of the stocks on the move featuring Dreadnought Resources (ASX:DRE), Patrys...
Read ArticleShareCafeGlobal recession fears weigh in: ASX down 1.6% at noon by Lauren Hayes US stocks closed t...
Read ArticleShareCafeStocks of the Hour: DRE, PAB, STK Dreadnought Resources (ASX:DRE)...
Read ArticlePatrys crosses blood brain barrier in health animals Cynata receives Notice of Acceptance from IP A...
Read ArticleTherapeutic antibody development company Patrys (ASX:PAB) has announced new preclinical data...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleThe ASX is set to open much lower on Monday Wall Street plunged on Friday as earnings season starts...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleOncology company Patrys (PAB) completes specification tests of drug substance from its lead PAT-DX1...
Read ArticleHighlights: The ASX 200 benchmark index closed up today (26 August), gaining 0.79% to end the da...
Read ArticleThe Victorian government awards Patrys (PAB) a $100,000 Victorian Medical Research Acceleration Fun...
Read ArticlePatrys gets research grant to progress lead drug Next Science gets Canada license Bad news for ID...
Read ArticleTherapeutic antibody development company Patrys (ASX:PAB) has announced new pre-clinical dat...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticlePatrys (ASX:PAB) has announced that its contract development manufacturing organisation has...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticlePatrys’ (PAB) Contract Development Manufacturing Organisation (CDMO) has completed the second engin...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleEmerging Companies (XEC) index tumbles 2.8% Benchmark ASX200 down 7% over five sessions Square...
Read ArticlePatrys (PAB) sees a range of PAT-DX1 studies published in peer-reviewed journal ImmunoHorizons supp...
Read ArticlePatrys (PAB) receives $250,000 in funding to support its research on treatments for brain cancer Th...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleTherapeutic antibody development company Patrys (ASX:PAB) has identified and selected an opt...
Read ArticleTherapeutic antibody development company Patrys (PAB) identifies and selects an optimised stable ce...
Read Article“With this key reagent now identified and in hand, we can rapidly move into developing a commercial-...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read ArticleIn a newsletter on Tuesday, CEO and managing director Dr James Campbell outlined the growing upside...
Read ArticleThe S&P/ASX200 climbed into the close on Tuesday. Most of the 35 or so point gain (0.5%) comes...
Read ArticleWhen markets get the jitters, smaller companies are often in the firing line and ASX microcaps have...
Read ArticleThe ASX 200 Health Index (XHJ) is falling by 0.3% at the time of writing, compared to the broader in...
Read ArticleThe company's wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has also received a $1,188,581 R&...
Read ArticlePatrys (PAB) completes the first engineering run of its cancer antibody candidate, PAT-DX1, resulti...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleThe ‘Covid-induced trial, interrupted syndrome’ is no more apparent than within the walls of Imagion...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read Article“Having two assets on the path to the clinic is a very exciting place to be, and makes Patrys a much...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticleHe’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radi...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read Article“Based on the promising data we have seen for PAT-DX3 since we announced it 12 months ago, we believ...
Read ArticleThe ASX 200 Health Index (XHJ) is up by 1.30% at the time of writing, compared to the broader index...
Read ArticlePatrys (PAB) will be undertaking a $7.8 million capital raising, consisting of a placement and a fu...
Read ArticleAfter a positive Monday to Thursday, the ASX wiped out gains made across the week, losing more than...
Read ArticleLocal stocks lost ground on Thursday, with minor falls at the big end of town and a slightly steeper...
Read Article“This quarter has delivered a period of significant momentum for Patrys. We have continued to build...
Read ArticlePatrys (ASX:PAB) has announced data from its completed pre-clinical study that has demonstra...
Read ArticleIt’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for in...
Read Article“This preclinical study has shown that the affinity our deoxymabs have for DNA is sufficient for the...
Read ArticlePatrys (PAB) has shown its antibody can be used as a targeting agent to deliver anti-cancer drugs t...
Read ArticleBoth Amplia and Patrys have flagship drugs in development that take unique approaches to tackling ca...
Read ArticleIts primary focus is to move its lead asset, PAT DX1, a small antibody fragment, to the first human...
Read ArticleIts primary focus is to move its lead asset, PAT DX1, a small antibody fragment, to the first human...
Read ArticleStockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) per...
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read ArticleLocal stocks lost ground on Thursday as a tone of caution emerged in Asian trade, ahead of the US Fe...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticleTrading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers a...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleThe ASX closed in negative territory despite a solid gain in tech stocks. The ASX 200 closed 0.23% d...
Read ArticlePatrys Limited (ASX: PAB) shares are tumbling in late morning trade. At the time of writing, the Pa...
Read ArticleASX 200 health stocks index fell by 0.12% this morning, compared to the broader index which fell by...
Read ArticleStockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) per...
Read ArticlePatrys (ASX:PAB) says new preclinical data from the Garvan Institute of Medical Research has...
Read ArticleASX 200 health stocks index rose by 0.68% this morning, compared to the broader index which rose by...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleTherapeutic antibody development company Patrys (ASX:PAB) has announced new data from non-cl...
Read ArticleThe Patrys Limited (ASX: PAB) share price is starting the week on a strong note. This comes after t...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleEach week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength In...
Read ArticleAsk A Fund Manager The Motley Fool chats with fund managers so that you can get an insight into how...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading d...
Read ArticleFertoz Ltd (ASX:FTZ) topped the pops with a red hot 14-day RSI of 93 after two massive days to finis...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading d...
Read ArticleSummary After the launch update of Aussie BubsTM-branded formula range on Walmart.com, the BUB s...
Read ArticleRecent advances in our still-shallow understanding of the human brain have led to a renewed interest...
Read ArticleSummary The ASX 200 breached 7,400 level for the first time to hit a fresh high of 7,406.20. Th...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading d...
Read ArticleSummary Neuroprotective drug developer Argenica Therapeutics commenced trading on the ASX after...
Read ArticleSummary The ASX 200 was trading higher by 12.70 points or 0.17% at 7315.20 by mid-session, led b...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleIt was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies relea...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at th...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at th...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike....
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read ArticleSummary Two directors of Australia’s Crown Resorts Ltd (ASX:CWN) resigned just a day after a rep...
Read ArticleSummary Melbourne based biotech company Patrys Limited has selected an optimised stable cell lin...
Read ArticleSummary After raising A$7.3 million via a placement, the company is now sufficiently funded to a...
Read ArticleThe funds raised through the placement and rights issue will position the company to effectively lev...
Read ArticleTherapeutic antibody development company Patrys (ASX:PAB) has announced the Australian paten...
Read ArticleTherapeutic antibody development company Patrys (ASX: PAB) has been granted an Australian patent cov...
Read ArticleAustralian antibody development company Patrys (ASX:PAB) says it has completed initial produ...
Read ArticleA quick wrap of the ASX’s key winners and losers on Wednesday, September 16. Data is taken after the...
Read ArticleA quick wrap of the ASX’s key winners and losers on Tuesday, September 15. Data is taken after the m...
Read ArticleA quick wrap of the ASX’s key winners and losers on Wednesday, September 9. Data is taken after the...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticlePatrys (ASX:PAB) has announced a fully underwritten and non-renounceable rights issue to rai...
Read ArticleOn Stockhead today, how a ‘tired’ gold mine transformed shell company Bellevue into a $650m market d...
Read ArticleMelbourne-based therapeutic antibody development company Patrys (ASX:PAB) has announced the...
Read ArticleMelbourne-based therapeutic antibody development company Patrys (ASX:PAB) has announced the...
Read ArticleStockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and pickin...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleAustralian company Patrys (ASX:PAB), a therapeutic antibody development company, has announc...
Read ArticleAccording to CEO and managing director Dr James Campbell, “Following ongoing discussions at...
Read ArticleIt’s shaping up as another coronavirus-related bloodbath on local markets this morning. But within t...
Read ArticleA pre-clinical animal study by Australian therapeutic antibody company Patrys (ASX: PAB) has shown t...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticlePatrys (ASX:PAB), an Australian therapeutic antibody development company, has announced the...
Read ArticleThe health sector was the most successful sector on the ASX in 2019. Various small caps made several...
Read ArticleIn 2019 the culmination of decades worth of work turned several biotechs and life sciences companies...
Read ArticleThe Small-cap stocks have the potential to deliver higher returns within a shorter span of time. As...
Read ArticlePrescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is i...
Read ArticleTherapeutic antibody developer Patrys (ASX: PAB) has revealed new pre-clinical animal data that poin...
Read ArticleBiotech company Patrys Limited (ASX:PAB) shares got a bump this morning, after some more positive an...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleThe cancer drug developer adheres to that perverse law of diminishing returns that states: “The more...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
